subscribeSubscribe
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib
GLOBENEWSWIRE
06 Mar 2024
Share Share
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer

Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
ENDPTS
26 Jan 2024
Share Share
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
BUSINESSWIRE
22 Jan 2024
Share Share
Latest PIII trial data investigating Cabometyx to be presented at ASCO GU 2024

Latest PIII trial data investigating Cabometyx to be presented at ASCO GU 2024
GLOBENEWSWIRE
22 Jan 2024
Share Share
European Patent Office Rules in Favor of Exelixis on Formulation Patent

European Patent Office Rules in Favor of Exelixis on Formulation Patent
BUSINESSWIRE
18 Jan 2024
Share Share
Results from Phase 3 Evaluating Cabozantinib in Neuroendocrine Tumors Presented

Results from Phase 3 Evaluating Cabozantinib in Neuroendocrine Tumors Presented
PRESS RELEASE
22 Oct 2023
Share Share
Exelixis ends Cabometyx study after seeing dramatic improvements

Exelixis ends Cabometyx study after seeing dramatic improvements
Zoey Becker FIERCE PHARMA
25 Aug 2023
Share Share
Exelixis, Teva reach settlement on Cabometyx patent dispute

Exelixis, Teva reach settlement on Cabometyx patent dispute
Paul Schloesser ENDPTS
25 Jul 2023
Share Share
Roche, Exelixis` Tecentirq-Cabometyx fails a 3rd time

Roche, Exelixis` Tecentirq-Cabometyx fails a 3rd time
Angus Liu FIERCE PHARMA
04 Mar 2023
Share Share
Exelixis Provides Update on PIII Trial Evaluating Cabozantinib with Atezolizumab

Exelixis Provides Update on PIII Trial Evaluating Cabozantinib with Atezolizumab
BUSINESSWIRE
02 Mar 2023
Share Share